Scinai Immunotherapeutics (SCNI) Operating Expenses (2014 - 2024)

Scinai Immunotherapeutics has disclosed Operating Expenses across 11 years of filings, most recently posting $14.0 million for Q4 2024.

• Operating Expenses for Q4 2024 came in at $14.0 million, down 20.29% year-over-year; the trailing twelve-month figure through Dec 2025 was $11.8 million (up 47.05% YoY), and the FY2025 annual result was -$5.4 million, down 167.15% from the prior year.
• Operating Expenses came in at $14.0 million for Q4 2024 at Scinai Immunotherapeutics, up from -$2.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $55.6 million in Q3 2020 to a low of -$13.0 million in Q4 2021.
• The 5-year median for Operating Expenses is $2.8 million (2022), against an average of $6.6 million.
• Across the five-year window, Operating Expenses tumbled 2729.51% in 2020 and soared 482.03% in 2023, its largest moves.
• Scinai Immunotherapeutics' Operating Expenses stood at $12.1 million in 2020, then tumbled by 207.25% to -$13.0 million in 2021, then jumped by 123.23% to $3.0 million in 2022, then jumped by 482.03% to $17.6 million in 2023, then fell by 20.29% to $14.0 million in 2024.
• The last three Operating Expenses figures came in at $14.0 million (Q4 2024), -$2.2 million (Q3 2024), and -$5.7 million (Q2 2024), per Business Quant data.